14.79
0.20%
+0.03
After Hours:
14.78
-0.010
-0.07%
Bausch + Lomb Corp stock is currently priced at $14.79, with a 24-hour trading volume of 180.46K.
It has seen a +0.20% increased in the last 24 hours and a -12.59% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $14.80 pivot point. If it approaches the $14.66 support level, significant changes may occur.
Previous Close:
$14.76
Open:
$14.8
24h Volume:
180.46K
Market Cap:
$5.19B
Revenue:
$4.15B
Net Income/Loss:
$-260.00M
P/E Ratio:
-24.95
EPS:
-0.5929
Net Cash Flow:
$-198.00M
1W Performance:
+1.02%
1M Performance:
-12.59%
6M Performance:
-6.98%
1Y Performance:
-12.74%
Bausch + Lomb Corp Stock (BLCO) Company Profile
Name
Bausch + Lomb Corp
Sector
Industry
Phone
905-695-7700
Address
520 Applewood Crescent, Vaughan
Bausch + Lomb Corp Stock (BLCO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-12-23 | Initiated | Stifel | Hold |
Oct-03-23 | Resumed | Evercore ISI | Outperform |
May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
Mar-09-23 | Initiated | Needham | Hold |
Dec-21-22 | Initiated | Barclays | Equal Weight |
Sep-12-22 | Initiated | H.C. Wainwright | Buy |
Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
Jun-24-22 | Initiated | Evercore ISI | Outperform |
Jun-06-22 | Initiated | Citigroup | Buy |
May-31-22 | Initiated | Deutsche Bank | Hold |
May-31-22 | Initiated | Goldman | Neutral |
May-31-22 | Initiated | Guggenheim | Buy |
May-31-22 | Initiated | JP Morgan | Neutral |
May-31-22 | Initiated | Jefferies | Buy |
May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
May-31-22 | Initiated | Wells Fargo | Overweight |
May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch + Lomb Corp Stock (BLCO) Latest News
Earnings Preview: Alignment Healthcare (ALHC) Q1 Earnings Expected to Decline
Zacks Investment Research
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Zacks Investment Research
All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy
Zacks Investment Research
BLCO or AVTR: Which Is the Better Value Stock Right Now?
Zacks Investment Research
BLCO or AVTR: Which Is the Better Value Stock Right Now?
Zacks Investment Research
Bausch + Lomb Corp Stock (BLCO) Financials Data
Bausch + Lomb Corp (BLCO) Revenue 2024
BLCO reported a revenue (TTM) of $4.15 billion for the quarter ending December 31, 2023, a +10.03% rise year-over-year.
Bausch + Lomb Corp (BLCO) Net Income 2024
BLCO net income (TTM) was -$260.00 million for the quarter ending December 31, 2023, a -4,433% decrease year-over-year.
Bausch + Lomb Corp (BLCO) Cash Flow 2024
BLCO recorded a free cash flow (TTM) of -$198.00 million for the quarter ending December 31, 2023, a -216.47% decrease year-over-year.
Bausch + Lomb Corp (BLCO) Earnings per Share 2024
BLCO earnings per share (TTM) was -$0.74 for the quarter ending December 31, 2023, a -5,275% decline year-over-year.
About Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Cap:
|
Volume (24h):